June 2016—HTG Molecular Diagnostics entered into a research collaboration agreement with Bristol-Myers Squibb to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types.
Read More »HTG, Illumina agreement
January 2015—HTG Molecular Diagnostics has entered into an agreement with Illumina in which HTG will have the right to develop certain in vitro diagnostic test kits that use Illumina sequencing technology.
Read More »microRNA whole transcriptome assay, 8/14
August 2014—HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of 2,275 human microRNAs described in the miRBase v20 database.
Read More »HTG Molecular Diagnostics and OvaGene Oncology partner, 6/14
June 2014—HTG Molecular Diagnostics and OvaGene Oncology entered a manufacturing supply agreement in which OvaGene will design and develop its proprietary gene expression assays on HTG’s fully automated, extraction-free Edge Platform.
Read More »Validation of blood test for heart transplant rejection, 12/13
December 2013—The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients and thereby allow doctors to better monitor and treat patients post-transplant. It is the first clinical validation study of this kind in Canada.
Read More »